Evidence map›Paper›PMID 31548185›Full record

ArticleAntimicrobial agents and chemotherapy2019

Population Pharmacokinetics of Doxycycline in Children.

Elizabeth J Thompson, Huali Wu, Chiara Melloni, Stephen Balevic, Janice E Sullivan, Matthew Laughon, Kira M Clark, Rohit Kalra, Susan Mendley, Elizabeth H Payne and 6 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01431326 (Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01431326 completednot on this map

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

TypeobservationalSponsorDaniel BenjaminRan2011 to 2019Enrolled3,520ConditionsAdenovirus, Anesthesia, Anxiety, AnxiolysisArmsThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Elizabeth J ThompsonDepartment of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Huali WuDuke Clinical Research Institute, Durham, NC, USA.
Chiara MelloniDuke Clinical Research Institute, Durham, NC, USA.
Stephen BalevicDepartment of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Janice E SullivanUniversity of Louisville, Norton Children's Hospital, Louisville, KY, USA.
Matthew LaughonUniversity of North Carolina, Chapel Hill, NC, USA.
Kira M ClarkDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, USA.
Rohit KalraAnn & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
Susan MendleyUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Elizabeth H PayneThe Emmes Company, LLC, Rockville, MD, USA.
Jinson ErinjeriThe Emmes Company, LLC, Rockville, MD, USA.
Casey E GelberThe Emmes Company, LLC, Rockville, MD, USA.
Barrie HarperDuke Clinical Research Institute, Durham, NC, USA.
Michael Cohen-WolkowiezDepartment of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Christoph P HornikDepartment of Pediatrics, Duke University Medical Center, Durham, NC, USA christoph.hornik@duke.edu.
Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Clinical Research Institute · USDuke Medical Center · USEmmes (United States) · USUniversity of North Carolina at Chapel Hill · USLurie Children's Hospital · USOregon Health & Science University · USUniversity of Louisville · USUniversity of Maryland, Baltimore · USKosair Children's Hospital · US

Funding

COVID-19 Supplement - Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)U24TR001608 · NCATS · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K., BERNARD, GORDON RAPHAEL · 2016 to 2022
$177.0M
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
Global Pediatric Clinical Trials NetworkU18FD006298 · FDA · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL, HORNIK, CHRISTOPH · 2017 to 2021
$5.5M
Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in ChildrenR01HD076676 · NICHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2014 to 2017
$2.6M
Mentoring in Clinical Pharmacology and Early Phase TrialsK24AI143971 · NIAID · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2019 to 2023
$895k
Pharmacokinetics, Pharmacodynamics, and Safety of Methylprednisolone in Neonates on Cardiopulmonary BypassK23HD090239 · NICHD · DUKE UNIVERSITY · PI HORNIK, CHRISTOPH · 2017 to 2020
$646k
Mentorship of Early-Career Clinicians in Bronchopulmonary Dysplasia Drug TherapiesK24HL143283 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAUGHON, MATTHEW · 2019 to 2023
$613k
FDA HHS U18 FD006298NCATS NIH HHS U24 TR001608NHLBI NIH HHS K24 HL143283NIAID NIH HHS HHSN272201300017CNIAID NIH HHS HHSN272201300017INIAID NIH HHS HHSN272201500006CNIAID NIH HHS K24 AI143971NICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INICHD NIH HHS HHSN275201800003INICHD NIH HHS K23 HD090239NICHD NIH HHS R01 HD076676NIGMS NIH HHS T32 GM086330
6 · The paper itself

Abstract

Doxycycline is a tetracycline-class antimicrobial labeled by the United States (U.S.) Food and Drug Administration for children >8 years of age for many common childhood infections. Doxycycline is not labeled for children ≤8 years of age, due to the association between tetracycline class antibiotics and tooth staining, although doxycycline may be used off-label in severe conditions. Accordingly, there is a paucity of pharmacokinetic (PK) data to guide dosing in children 8 years and younger. We leveraged opportunistically-collected plasma samples after intravenous (IV) and oral doxycycline doses received per standard of care to characterize the PK of doxycycline in children of different ages, and evaluated the effect of obesity and fasting status on PK parameters.We developed a population PK model of doxycycline using data collected from 47 patients 0-18 years of age, including 14 participants ≤8 years. We developed a 1 compartment PK model and found doxycycline clearance to be 3.32 L/h/70 kg and volume to be 96.8 L/70kg for all patients; comparable to values reported in adults. We estimated a bioavailability of 89.6%, also consistent with adult data. Allometrically scaled clearance and volume of distribution did not differ between children 2 to ≤8 years of age and children >8 to ≤18 years of age, suggesting that younger children may be given the same per kg dosing. Obese and fasting status were not selected for inclusion in the final model. Additional doxycycline PK samples collected in future studies may be used to improve model performance and maximize its clinical value.

Identifiers

PMID31548185
PMCPMC6879254
OpenAlexW2976079483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.